Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
Authors:
- Geert A. A. VersteegGVGeert A. A. Versteeg
- Maxim J. P. RooijakkersMRMaxim J. P. Rooijakkers
- Niels A. StensNSNiels A. Stens
- Marleen H. van WelyMWMarleen H. van Wely
- Robert-Jan M. van GeunsRGRobert-Jan M. van Geuns
- Leen A. F. M. van GarsseLGLeen A. F. M. van Garsse
- Guillaume S. C. GeuzebroekGGGuillaume S. C. Geuzebroek
- Michel W. A. VerkroostMVMichel W. A. Verkroost
- Dick H. J. ThijssenDTDick H. J. Thijssen
- Robin H. HeijmenRHRobin H. Heijmen
- Lokien X. van NunenLNLokien X. van Nunen
- Niels van RoyenNRNiels van Royen
- 8 August 2025
- journal article
- video audio-media
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 222,p. e68470
Abstract
Transcatheter aortic valve implantation (TAVI) requires multiple access sites, each with a potential risk of access site-related bleeding complications. While most bleeding events occur at the primary TAVI access site, a significant number of bleeding events originate from the secondary access sites. Additionally, a temporary pacing lead prevents early mobilization after TAVI, while prolonged immobilization is associated with an increased rate of post-procedural complications such as delirium and infection. Using alternative secondary access sites may reduce the incidence of access site-related complications and facilitate early mobilization after TAVI. This protocol describes an upper-extremity approach, as recently investigated in the TAVI XS trial, and aims to provide a comprehensive overview of the methodology. For this approach, the radial artery is used for diagnostic access, and the upper arm veins (basilic, cephalic, or brachial vein) are used for temporary pacing lead insertion. To enhance reproducibility, a step-by-step protocol was created on how to perform an upper-extremity secondary access approach during transfemoral TAVI. It was previously demonstrated that an upper-extremity approach for secondary access results in significantly fewer clinically relevant secondary access site-related bleeding complications. Additionally, the approach reduces the time to mobilization for patients who require a pacing lead for an extended period of time. Due to the pragmatic nature of the aforementioned study, the protocol presented here is readily applicable to the majority of transfemoral TAVI patients. The upper-extremity approach reduces periprocedural complications in TAVI patients and may facilitate early mobilization. The presented approach is the next step in minimizing the invasiveness of transfemoral TAVI and should be considered in all eligible TAVI patients.Keywords
This publication has 21 references indexed in Scilit:
- Upper- vs Lower-Extremity Secondary Access During Transcatheter Aortic Valve ImplantationJAMA Network Open, 2024
- Contemporary Review of the Methods for Rapid Ventricular Pacing During Transcatheter Aortic Valve ReplacementStructural Heart, 2024
- Upper extremity versus lower extremity for secondary access during transcatheter aortic valve implantation: rationale and design of the randomised TAVI XS trialNetherlands Heart Journal, 2024
- Bleeding in Patients Undergoing Transfemoral Transcatheter Aortic Valve ReplacementJACC: Cardiovascular Interventions, 2023
- Bleeding Events After Transcatheter Aortic Valve ReplacementJACC, 2023
- Delirium After TAVRJACC: Cardiovascular Interventions, 2020
- Early mobilisation after transfemoral transcatheter aortic valve implantation: results of the MobiTAVI trialNetherlands Heart Journal, 2020
- Left Ventricular Rapid Pacing Via the Valve Delivery Guidewire in Transcatheter Aortic Valve ReplacementJACC: Cardiovascular Interventions, 2019
- Impact of the Use of Transradial Versus Transfemoral Approach as Secondary Access in Transcatheter Aortic Valve Implantation ProceduresThe American Journal of Cardiology, 2014
- Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trialThe Lancet, 2011